Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna MRNA, +11.80% CEO Stephane Bancel has left no doubt whether he's taking a glass half-full or half-empty approach to the emergence of the new omicron coronavirus variant.

Key Words: ‘This is not going to be good' — Moderna CEO on what scientists are telling him about the omicron coronavirus variant

Moderna CEO Stéphane Bancel told the FT he expected a "material drop" in the effectiveness of the existing vaccines, reigniting market jitters.

Oil heads for biggest monthly loss since March 2020, after Moderna boss questions vaccine effectiveness against Omicron

Moderna CEO Stephane Bancel predicts a 'material drop' in the effectiveness of current vaccines against the Omicron variant.

Moderna CEO Says Current Vaccines Likely to Struggle Against Omicron Variant

The chief executive of Moderna Therapeutics Inc (NASDAQ:MRNA) has predicted that existing vaccines will be less effective against the Omicron variant than other strains of coronavirus. In an interview with the Financial Times, Stéphane Bancel said the high number of Omicron mutations on the spike protein and the rapid spread of the variant in South Africa suggest that existing vaccines may need to be modified, which could take months.

Moderna boss predicts existing vaccines will be less effective against Omicron variant

HONG KONG/SYDNEY (Reuters) -Drugmaker Moderna's CEO set off fresh alarm bells in financial markets on Tuesday after he warned that COVID-19 vaccines were unlikely to be as effective against the Omicron variant as they have been against the Delta version.

Moderna CEO warns COVID-19 shots less effective against Omicron, spooks markets

Stéphane Bancel told the Financial Times "there is no world" where current vaccines will fight the Omicron variant as effectively as they've fought the Delta variant.

Moderna's CEO doubtful the current crop of COVID-19 vaccines will be as effective against Omicron variant as they have been against Delta

U.S. stock futures tumbled anew on Tuesday after Moderna's chief executive officer Stéphane Bancel predicted that current vaccines would be less effective against the new omicron variant of COVID.

Market Snapshot: Stock futures tumble anew as Moderna CEO predicts existing vaccines will be less effective against omicron variant

BioNTech SE

Novavax

Pfizer

Another variant of the coronavirus, Omicron, is up on the WHO-identified list. Several mutations of this variant spark fears of high resistance to the COVID-19 vaccines.

Omicron Fears Fuel Rally in Vaccine Stocks: Will It Continue?

Amplify Travel Tech ETF

VanEck Vectors Biotech ETF

Amplify Video Game Tech ETF

iShares U.S. Pharmaceuticals ETF

United States Oil Fund LP

Direxion Work From Home ETF

Technology Select Sector SPDR Fund

The emergence of a new coronavirus strain, namely Omicron, has caused a massacre on Wall Street on Friday. These ETFs could gain/lose in the coming days if Omicron cases continue to rise.

ETF Areas to Gain/Lose on Fear of Omicron Strain of Coronavirus

Johnson & Johnson

The omicron variant dealt the stock market a blow, but these vaccine stocks promise investors a way to cash in while combatting Covid-19. The post 5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market appeared first on InvestorPlace.

5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market

CVS Health

Check out these health care stocks that are heating up in the stock market right now.

4 Top Health Care Stocks To Watch In The Stock Market Today

All UK citizens over 18 will be offered a COVID-19 booster vaccine to deal with the potential impact of the omicron variant, the UK's vaccine advisory body the Joint Committee on Vaccine and Immunisation (JCVI) said today. It is a rapid step forward for a mutation that was only identified last week, but such in the concern surrounding the potential impact of the new strain spreading globally.

Omicron: All UK adults to get Pfizer of Moderna booster

On Monday, Moderna Inc. (NASDAQ:MRNA) shares edged higher after revealing plans to develop a vaccine for the Omicron variant.  The stock surged nearly 10% after it said a new covid vaccine targeting the Omicron variant could be ready by early 2022.

Should you buy Moderna stock as it develops a vaccine for the Omicron variant?

AstraZeneca

Fears about the Omicron variant of Covid-19 rattled the world's financial markets Friday and early Monday morning. But shares of the major coronavirus vaccine makers were getting a boost from the latest pandemic jitters.

Covid vaccine makers' stocks soar on Omicron variant concerns

"If we have to make a brand new vaccine, I think that's going to be early 2022 before that's really going to be available in large quantities."

Moderna extends 2-day gain to 32% after it says Omicron vaccine will be ready in early 2022

Moderna CEO Stephane Bancel told CNBC that it could take months to develop and ship an omicron specific vaccine, but a higher dose of its booster could be ready much sooner.

Moderna CEO says it will take months to clear a new Covid vaccine targeting omicron

The biotech is already hard at work developing a vaccine against the worrisome omicron variant.

Why Moderna Stock Is Spiking Today

Shares of Moderna Inc. MRNA, +20.57% shot up 10.1% in premarket trading Monday, after soaring 20.7% in the previous session, on hopes for the quick development of an omicron-specific COVID-19 booster vaccine. The biotechnology company's stock rallied on Friday after the company said it will "rapidly advance" a booster vaccine candidate.

Moderna's stock shoots up again on hopes of a 'brand new' omicron vaccine by early next year

Can Moderna Beat the Omicron Variant?

The vaccine maker says a reformulated vaccine to tackle the Omicron variant could be ready in early 2022.

Moderna Says Vaccine for Omicron Variant Could Be Ready in Early 2022

The stock price of Moderna Inc (NASDAQ: MRNA) increased by over 10% pre-market today. This is why it happened.

Moderna (MRNA) Stock: Why The Price Jumped Today

Airbnb

Affirm

Confluent

Colfax

Colfax Corp - Units

Dell Technologies

DocuSign

Expedia

Five9

Illumina

Lemonade

MongoDB

monday.com

Netflix

ServiceNow

Okta

PayPal

Take-Two Interactive Software

Twilio

Upstart Holdings

VMware

Zoom Video

Sharp sell-offs can reveal great stock ideas if you surface the right stocks that contrary to the market action close positive. When picking names that close in the green, make sure they are well known and of a higher market cap. They tend to have sustainable rallies when they turn around.

Forget The Covid Apocalypse, Focus On Stocks That Closed Green After Friday's Monster Sell Off

The shares of Moderna Inc (NASDAQ: MRNA) have received a $348 price target from Piper Sandler. These are the details.

Moderna (MRNA) Stock: $348 Price Target From Piper Sandler

Even as the new highly-mutated strain of the coronavirus, named omicron, threatens the fledgling post-pandemic recovery across the globe, biopharma companies are ramping up efforts to help. What Happened: Moderna, Inc. (NASDAQ: MRNA), which was the second biopharma company to get authorization for a COVID-19 vaccine, is confident it will have something on the table shortly to tackle the latest virus threat.

Moderna May Have a New Vaccine For Omicron COVID Strain By Early 2022

The omicron variant should gives these top vaccine stocks a healthy boost this week.

News for Moderna Stock (MRNA)